Companies / Health Care / Biotechnology
AbbVie stock buybacks
ABBV$1.5Bbought back in the 12 months to Jun 30, 2026
AbbVie bought back $1.5B of its stock in the last twelve months, $529M more than it paid out in stock compensation. Its share count is up 0.0% from a year earlier.
Show as table
| Period | Value |
|---|---|
| Q3 '20 | $20M |
| Q4 '20 | $296M |
| Q1 '21 | $787M |
| Q2 '21 | $10M |
| Q3 '21 | $6M |
| Q4 '21 | $131M |
| Q1 '22 | $1.5B |
| Q2 '22 | $9M |
| Q3 '22 | $4M |
| Q4 '22 | $4M |
| Q1 '23 | $2.0B |
| Q2 '23 | $10M |
| Q3 '23 | $4M |
| Q4 '23 | $3M |
| Q1 '24 | $1.3B |
| Q2 '24 | $9M |
| Q3 '24 | $17M |
| Q4 '24 | $358M |
| Q1 '25 | $961M |
| Q2 '25 | $12M |
| Q3 '25 | $4M |
| Q4 '25 | $3M |
| Q1 '26 | $1.5B |
| Q2 '26 | $9M |
Show as table
| Period | Value |
|---|---|
| Q3 '20 | 1.77B |
| Q4 '20 | 1.79B |
| Q1 '21 | 1.77B |
| Q2 '21 | 1.78B |
| Q3 '21 | 1.78B |
| Q4 '21 | 1.78B |
| Q1 '22 | 1.78B |
| Q2 '22 | 1.78B |
| Q3 '22 | 1.78B |
| Q4 '22 | 1.78B |
| Q1 '23 | 1.78B |
| Q2 '23 | 1.77B |
| Q3 '23 | 1.77B |
| Q4 '23 | 1.77B |
| Q1 '24 | 1.77B |
| Q2 '24 | 1.77B |
| Q3 '24 | 1.77B |
| Q4 '24 | 1.78B |
| Q1 '25 | 1.77B |
| Q2 '25 | 1.77B |
| Q3 '25 | 1.77B |
| Q4 '25 | 1.78B |
| Q1 '26 | 1.77B |
| Q2 '26 | 1.77B |
$9Mlast quarter (Q2 2026)
$529Mnet of stock compensation ($976M)
0.0%diluted shares, 1 year
+6.0%diluted shares, 5 years
$12.0Bdividends, 12 months
8%of free cash flow ($18.2B) spent on buybacks
$0raised by issuing stock, 12 months
$1.8Bleft under its authorization as of Jun 30, 2026
By fiscal year
Questions
- Does AbbVie buy back its stock?
- AbbVie bought back $1.5B of its stock in the last twelve months, $529M more than it paid out in stock compensation. Its share count is up 0.0% from a year earlier.
- How much did AbbVie spend on buybacks in fiscal 2025?
- $980M, according to its 10-K for the fiscal year ending Dec 31, 2025.
- Is AbbVie's share count going down?
- Its diluted share count changed +6.0% over five fiscal years and 0.0% over the last year.
- Does AbbVie have a buyback authorization?
- Its filings show $1.8B remaining under its repurchase authorization as of Jun 30, 2026.
Latest filing used: 10-Q for the period ending Jun 30, 2026, filed Aug 3, 2026 · open on SEC.gov